Estrogen and movement disorders

Clinical Neuropharmacology

Volumn 22, Issue 6, 1999, Pages 318-326

  Kompoliti, Katie ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Dopaminergic effects; Estrogen; Menopause; Movement disorders; Neuroprotection

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; PIPERAZINE ESTRONE SULFATE;

ARTICLE; BEHAVIOR; CHOREA; CLINICAL FEATURE; DISEASE COURSE; DOPAMINERGIC SYSTEM; DYSTONIA; ESTROGEN THERAPY; FEMALE; GENETIC RISK; HUMAN; MENSTRUATION; MOTOR DYSFUNCTION; MYOCLONUS; NEUROPROTECTION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL;

ANIMALS; BASAL GANGLIA; DOPAMINE AGENTS; ESTROGENS; FORECASTING; HUMANS; MOVEMENT DISORDERS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0032746406     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Van Hartesveldt C, Joyce JN. Effects of estrogen on the basal ganglia. Neurosci Biobehav Rev 1986;10:1-14.
2. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603-6.
3. Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection [see comments]. Am J Obstet Gynecol 1989;161:1832-41.
4. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-8.
5. Johnson SR. The clinical decision regarding hormone replacement therapy. Endocrinol Metab Clin North Am 1997;26:413-35.
6. Dluzen DE, McDermott JL, Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J Neurochem 1996;66:658-66.
7. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 1998;844:153-65.
8. Yu YL, Wagner GC. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J Neural Transm Park Dis Dement Sect 1994;8:215-21.
9. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res 1997;764:9-16.
10. Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol 1998; 345:207-11.
11. Shughrue PJ, Dorsa DM. Gonadal steroids modulate the growth-associated protein GAP-43 (neuromodulin) mRNA in postnatal rat brain. Brain Res Dev Brain Res 1993;73:123-32.
12. Shughrue PJ, Dorsa DM. Estrogen modulates the growth-associated protein GAP-43 (neuromodulin) mRNA in the rat preoptic area and basal hypothalamus. Neuroendocrinology 1993;57:439-47.
13. Diaz H, Lorenzo A, Carrer HF, Caceres A. Time lapse study of neurite growth in hypothalamic dissociated neurons in culture: sex differences and estrogen effects. J Neurosci Res 1992;33:266-81.
14. Naftolin F, Leranth C, Perez J, Garcia-Segura LM. Estrogen induces synaptic plasticity in adult primate neurons. Neuroendocrinology 1993;57:935-9.
15. Bedard PJ, Langelier P, Dankova J, et al. Estrogens, progesterone, and the extrapyramidal system. Adv Neurol 1979;24:411-22.
16. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system [letter]. Lancet 1977;2:1367-8.
17. Villeneuve A, Langlier P, Bedard P. Estrogens, dopamine and dyskinesias. Can Psychiatr Assoc J 1978;23:68-70.
18. Naik SR, Kelkar MR, Sheth UK. Attenuation of stereotyped behaviour by sex steroids. Psychopharmacology (Berl) 1978;57: 211-4.
19. Nausieda PA, Koller WC, Weiner WJ, Klawans HL. Modification of postsynaptic dopaminergic sensitivity by female sex hormones. Life Sci 1979;25:521-6.
20. Koller WC, Weiner WJ, Klawans HL, Nausieda PA. Influence of female sex hormones on neuroleptic-induced behavioral supersensitivity. Neuropharmacology 1980;19:387-91.
21. Barber PV, Arnold AG, Evans G. Recurrent hormone dependent chorea: effects of oestrogens and progestogens. Clin Endocrinol (Oxf) 1976;5:291-3.
22. Robinson RO, Stutchfield P, Hicks B, Marsden CD. Estrogens and dyskinesia [letter]. Neurology 1984;34:404-5.
23. Gordon JH. Modulation of apomorphine-induced stereotypy by estrogen: time course and dose response. Brain Res Bull 1980;5:679-82.
24. Di Paolo T, Poyet P, Labrie F. Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. Eur J Pharmacol 1981;73:105-6.
25. Chiodo LA, Caggiula AR, Saller CF. Estrogen potentiates the stereotypy induced by dopamine agonists in the rat. Life Sci 1981;28: 827-35.
26. Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem 1995;65:1651-7.
27. Di Paolo T, Rouillard C, Bedard P. 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur J Pharmacol 1985;117:197-203.
28. Becker JB. Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release. Synapse 1990;5:157-64.
29. Becker JB. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci Lett 1990;118:169-71.
30. Di Paolo T, Carmichael R, Labrie F, Raynaud JP. Effects of estrogens on the characteristics of [3H]spiroperidol and [3H]RU24213 binding in rat anterior pituitary gland and brain. Mol Cell Endocrinol 1979;16:99-112.
31. Hruska RE, Silbergeld EK. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980;208:1466-8.
32. Hruska RE, Silbergeld EK. Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur J Pharmacol 1980;61: 397-400.
33. McDermott JL, Liu B, Dluzen DE. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol 1994;125:306-11.
34. Morissette M, Levcsque D, Belanger A, Di Paolo T. A physiological dose of estradiol with progesterone affects striatum biogenic amines. Can J Physiol Pharmacol 1990;68:1520-6.
35. Holzbauer M, Youdim MB. The oestrous cycle and monoamine oxidase activity. Br J Pharmacol 1973;48:600-8.
36. Tao X, Shu-Leong H, Ramsden D. Estrogen can down-regulate the human catechol-O-methyltransferase gene expression: its implication in Parkinson's disease [abstract]. Mov Disord 1998;13:A114.
37. Gomez-Mancilla B, Bedard PJ. Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys. Neurosci Lett 1992;135:129-32.
38. Bedard PJ, Boucher R. Estradiol can suppress haloperidol-induced supersensitivity in dyskinetic monkeys. Neurosci Lett 1986;64: 206-10.
39. Miller JC. Sex differences in dopaminergic and cholinergic activity and function in the nigro-striatal system of the rat. Psychoneuroendocrinology 1983;8:225-36.
40. Smith RL, Van Hartesveldt C. Effects of ovariectomy and estrogen replacement on intrastriatal dopamine-elicited postural deviation. Pharmacol Biochem Behav 1985;22:689-93.
41. Euvrard C, Oberlander C, Boissier JR. Antidopaminergic effect of estrogens at the striatal level. J Pharmacol Exp Ther 1980;214: 179-85.
42. Euvrard C, Labrie F, Boissier JR. Effect of estrogen on changes in the activity of striatal cholinergic neurons induced by DA drugs. Brain Res 1979;169:215-20.
43. Bedard PJ, Boucher R, Dankova J, Langelier P. Female sexual hormones influence motor behaviour in rats after lesion of the entopeduncular nucleus. Neurosci Lett 1980;17:89-94.
44. Pittman KJ, Fibiger HC. The effects of estrogen on apomorphine-induced hypothermia and stereotypy in the rat. Neuropharmacology 1983;22:587-92.
45. Dupont A, Di Paolo T, Gagne B, Barden N. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats. Neurosci Lett 1981; 22:69-74.
46. Chiodo LA, Caggiula AR, Sailer CF. Estrogen increases both spiperone-induced catalepsy and brain levels of [3H]spiperone in the rat. Brain Res 1979;172:360-6.
47. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.
48. Paulson HL, Stern MB. Clinical manifestations of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic principles and practice. New York: McGraw-Hill, 1997: 183-199.
49. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic principles and practice. New York: McGraw-Hill, 1997:138-152.
50. Ashok PP, Radhakrishnan K, Sridharan R, Mousa ME. Epidemiology of Parkinson's disease in Benghazi, north-east Libya. Clin Neurol Neurosurg 1986;88:109-13.
51. D'Alessandro R, Gamberini G, Granieri E, Benassi G, Naccarato S, Manzaroli D. Prevalence of Parkinson's disease in the Republic of San Marino. Neurology 1987;37:1679-82.
52. Imaizumi Y, Kaneko R. Rising mortality from Parkinson's disease in Japan, 1950-1992. Acta Neurol Scand 1995;91:169-76.
53. Kurtzke JF, Murphy FM. The changing patterns of death rates in parkinsonism. Neurology 1990;40:42-9.
54. Li SC, Schoenberg BS, Wang CC, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985;42:655-7.
55. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492-7.
56. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-82.
57. Rosati G, Granieri E, Pinna L, et al. The risk of Parkinson disease in Mediterranean people. Neurology 1980;30:250-5.
58. Sutcliffe RL, Prior R, Mawby B, McQuillan WJ. Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability. Acta Neurol Scand 1985;72:363-79.
59. Svenson LW, Platt GH, Woodhead SE. Geographic variations in the prevalence rates of Parkinson's disease in Alberta. Can J Neurol Sci 1993;20:307-11.
60. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Postmenopausal estrogen replacement therapy and Parkinson's disease: a population based study in Olmstead County, Minnesota [abstract]. Mov Disord 1998;13(suppl 2):51.
61. Weiner WJ, Shulman L, Singer C, Lefert R, Mash D. Menopause and estrogen replacement therapy in Parkinson's disease [abstract]. Neurology 1996;46:376-7.
62. Saunders-Pullman RJ, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1998;52:1417-21.
63. Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int J Neurosci 1989;45:119-22.
64. Sandyk R. Parkinsonism after hysterectomy [letter]. S Afr Med J 1982;61:574.
65. Naessen T, Lindmark B, Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 1997; 177:412-6.
66. Gratton L. Neuroleptiques, parkinsonisme, et schizophrenie. Union Med Can 1960;89:681-94.
67. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
68. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999;53:91-5.
69. Factor SA. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease. Mov Disord 1993;8:240-1.
70. Giladi N, Honigman S. Hormones and Parkinson's disease [letter]. Neurology 1995;45:1028-9.
71. Jong LT, Cornella CL, Jaglin JA. Menstrual-related cyclic changes in women with Parkinson's disease [abstract]. Neurology 1995;45: A337.
72. Kompoliti K, Jaglin JA, Cornella CL, Raman R, Leurgans S. Menstrual related fluctuations in women with Parkinson's disease [abstract]. Neurology 1998;50:A386.
73. Mizuta E, Yamasaki S, Nakatake M, Kuno S. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology 1993;43:1048-9.
74. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov Disord 1986;1:85-7.
75. Thulin P, Carter JH, Nichols MD, Kurth M, Nun JG. Menstrualcycle related changes in Parkinson's disease [abstract]. Neurology 1996;46:A376.
76. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50:1141-3.
77. Thulin PC, Filoteo JV, Roberts JW, O'Brien SA. Effects of hormone replacement therapy on cognitive and motor function in women with Parkinson's disease [abstract]. Neurology 1998;50: 280.
78. Thulin PC, O'Brien SA, Filoteo JV, Roberts JW. Effect of estrogen replacement therapy on memory in women with Parkinson's disease [abstract]. Mov Disord 1998;13:A56.
79. Nausieda PA, Grossman BJ, Koller WC, Weiner WJ, Klawans HL. Sydenham chorea: an update. Neurology 1980;30:331-4.
80. Nausieda PA, Koller WC, Weiner WJ, Klawans HL. Chorea induced by oral contraceptives. Neurology 1979;29:1605-9.
81. Zegart KN, Schwarz RH. Chorea gravidarum. Obstet Gynecol 1968;32:24-7.
82. Vinogradov S, Csernansky JG. Postpartum psychosis with abnormal movements: dopamine supersensitivity unmasked by withdrawal of endogenous estrogens? J Clin Psychiatry 1990;51: 365-6.
83. Malcolm AD. Chorea and the oral contraceptives. Br Med J 1971; 4:491.
84. Wadlington WB, Erlendson IW, Burr IM. Chorea associated with the use of oral contraceptives: report of a case and review of the literature. Clin Pediatr (Phila) 1981;20:804-6.
85. Bell RC, Smith RC. Tardive dyskinesia: characterization and prevalence in a statewide system. J Clin Psychiatry 1978;39:39-47.
86. Tepper SJ, Haas JF. Prevalence of tardive dyskinesia. J Clin Psychiatry 1979;40:508-16.
87. Crane GE. Dyskinesia and neuroleptics. Arch Gen Psychiatry 1968;19:700-3.
88. Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968;124 (suppl):40-8.
89. Glazer WM, Naftolin F, Moore DC, Bowers MB, MacLusky NJ. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology 1983;8:429-34.
90. Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982;32:547-9.
91. Villeneuve A, Cazejust T, Cote M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 1980;6:145-51.
92. Bressman SB, Fahn S, Burke RE. Paroxysmal non-kinesigenic dystonia. Adv Neurol 1988:50:403-13.
93. Duane DD. Spasmodic torticollis: clinical and biologic features and their implications for focal dystonia. Adv Neurol 1988;50:473-92.
94. Soland VL, Bhatia KP, Marsden CD. Sex prevalence of focal dystonias. J Neurol Neurosurg Psychiatry 1996;60:204-5.
95. Bonuccelli U, Nocchiero A, Napolitano A, et al. Domperidone-induced acute dystonia and polycystic ovary syndrome. Mov Disord 1991;6:79-81.
96. Herzog AG. Hormonal influences on spasmodic torticollis: a case report [letter], Mov Disord 1993;8:118-9.
97. Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. N Engl J Med 1986;315:993-7.
98. Peterson BS, Leckman JF, Scahill L. Naftolin F, Keefe D, Charest NJ, Cohen DJ. Steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome. Psychoneuroendocrinology 1992;17:553-63.
99. Lees AJ, Robertson M, Trimble MR, Murray NM. A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry 1984;47:1-8.
100. Sandyk R, Bamford CR, Iacono RP. Menstrual-related fluctuations in Tourette's syndrome. Int J Neurosci 1987;35:237-9.
101. Sandyk R, Bamford CR. Estrogen as adjuvant treatment of Tourette syndrome. Pediatr Neurol 1987;3:122.
102. Sandyk R, Bamford CR, Iacono RP. Sexual hormones in the pathophysiology of Tourette's syndrome. Int J Neurosci 1988;38:125-9.
103. Schwabe MJ, Konkol RJ. Menstrual cycle-related fluctuations of tics in Tourette syndrome. Pediatr Neurol 1992;8:43-6.
104. Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF. Postpartum obsessive compulsive disorder: a case series. J Clin Psychiatry 1993;54:156-9.
105. Sichel DA, Cohen LS, Rosenbaum JF, Driscoll J. Postpartum onset of obsessive-compulsive disorder. Psychosomatics 1993;34: 277-9.
106. Weiss M, Baerg E, Wisebord S, Temple J. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Can J Psychiatry 1995;40:205-7.
107. Biegon A. Effects of steroid hormones on the serotonergic system. Ann N Y Acad Sci 1990;600:427-32.
108. Peterson BS, Leckman JF, Scahill L, et al. Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol 1994;14:131-5.
109. Peterson BS, Zhang H, Anderson GM, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J Clin Psychopharmacol 1998; 18:324-31.
110. Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979;26:49-84.
111. Blum I, Vered Y, Lifshitz A, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci 1996;32:1158-62.
112. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995;37:434-41.
113. O' Connor LH, Feder HH. Estradiol and progesterone influence a serotonin mediated behavioral syndrome (myoclonus) in female guinea pigs: comparison with steroid effects on reproductive behavior. Brain Res 1984;293:119-25.
114. Biegon A, Reches A, Snyder L, McEwen BS. Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormones. Life Sci 1983;32:2015-21.
115. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996;16:325-44.
116. Biegon A, McEwen BS. Modulation by estradiol of serotonin receptors in brain. J Neurosci 1982;2:199-205.
117. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1997;48(suppl 7):S21-6.